

Human CDH17/Cadherin 17 Domain 7 Protein

Cat. No. CDH-HM2D3

Description

Source	Recombinant Human CDH17/Cadherin 17 Domain 7 Protein is expressed from HEK293 with hFc tag at the C-Terminus. It contains Ala668-Gly777.
Accession	Q12864
Molecular Weight	The protein has a predicted MW of 38.42 kDa. Due to glycosylation, the protein migrates to 48-52 kDa based on Tris-Bis PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE

Formulation and Storage


Formulation	Lyophilized from 0.22 µm filtered solution in 20mM Tris, 150mM NaCl (pH 8.0). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Liver-intestine cadherin (CDH17) has been known to function as a tumor stimulator and diagnostic marker for almost two decades. In vivo studies showed CDH17 knockout resulted in apoptotic PC tumor death through activating caspase-3 activity. Taken together, CDH17 functions as an oncogenic molecule critical to PC growth by regulating tumor apoptosis signaling pathways and CDH17 could be targeted to develop an anti-PC therapeutic approach.

Assay Data

Tris-Bis PAGE



Human CDH17 Domain 7 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.